Name: 글로벌 시장 동향
SKU: PH7808
Availability: InStock

보고서 요약(국문)

개요
전 세계 안구 림프종 치료 시장은 2022년 XX억 달러 규모에 도달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률을 보이며 2030년에는 XX억 달러에 이를 것으로 예상됩니다.
안구 림프종은 드문 유형의 B세포 림프종입니다. 림프구라고 불리는 백혈구에서 발생하며, 특히 50세 이상 또는 면역 체계가 약화된 사람들에게 흔합니다. 이 유형의 안구암 환자 중 상당수는 원발성 중추신경계 림프종(PCNSL)도 동반합니다.
전 세계 안구 림프종 치료 시장은 메토트렉세이트, 리툭시맙, 시스플라틴 등 다양한 약물을 포함합니다. 이 시장은 면역 체계가 약화된 사람들의 증가, 고령 인구 증가, 연구 발전 등의 요인에 의해 성장하고 있습니다.

시장 동향: 성장 요인 및 제약 요인
면역 체계가 약한 사람은 이 질환에 더 취약합니다.
HIV/AIDS 환자, 면역억제 치료를 받는 장기 이식 수혜자, 면역억제제를 복용하는 자가면역 질환 환자와 같이 면역 체계가 약한 사람들은 안구 림프종에 걸릴 위험이 훨씬 높습니다.
예를 들어, 미국 안과학회(American Academy of Ophthalmology)의 2022년 논문에 따르면, 면역 체계가 제대로 작동하지 않는 사람들은 원발성 안구 림프종(PIOL)에 걸릴 위험이 있습니다. 이 유형의 림프종은 거의 대부분 비호지킨 B세포 림프종으로, 망막과 눈 안의 유리체에서 발생할 수 있습니다.
또한, 미국 암 학회(American Cancer Society)의 2022년 논문에서도 면역 체계가 약화된 사람들은 비호지킨 림프종(NHL)에 걸릴 위험이 더 높다고 언급하고 있습니다. 일부 만성 감염은 면역 체계를 평소보다 더 힘들게 작동하게 하여 림프종 발병 위험을 높일 수 있습니다.
이러한 감수성 증가는 환자 수를 늘려 안구 림프종 치료제에 대한 수요를 촉진합니다. 제약 회사들은 면역력이 저하된 환자를 위한 특수 의약품 개발에 점점 더 집중하고 있으며, 이러한 취약 계층의 특정 요구 사항을 해결하기 위한 임상 시험 및 연구 활동을 장려하고 있습니다.
시장 동향: 제약 요인
암 치료 비용의 높은 부담은 특히 정부의 의료 지원이 제한적인 신흥국 및 개발도상국에서 심각한 세계적 부담입니다. 이러한 문제는 연구 개발 비용, 엄격한 규제 요건, 특허 보호 및 의료 접근성 제한에서 비롯됩니다. 제네릭 의약품 장려, 약가 협상, 건강 보험 적용 범위 확대, 연구 투자, 국제 협력 강화, 암 예방 및 조기 진단 강조와 같은 전략을 통해 이러한 부담을 완화할 수 있습니다.
세분화 분석
전 세계 안구 림프종 치료 시장은 유형, 약물 종류, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.

메토트렉세이트 부문은 안구 내 림프종 치료 시장 점유율의 약 41.2%를 차지했습니다.
메토트렉세이트 부문은 41.2%의 시장 점유율로 시장을 주도할 것으로 예상됩니다. 화학요법제인 메토트렉세이트는 안구 내 암세포 증식을 억제하는 효과가 뛰어나 안구 내 림프종 치료에 널리 사용됩니다. 메토트렉세이트는 입증된 효능, 신약 대비 상대적으로 저렴한 가격, 그리고 인정받은 치료 효과로 시장을 선도하고 있습니다.
또한, 증가하는 신약 승인 건수 역시 해당 부문의 성장을 견인할 것으로 예상됩니다. 예를 들어, 2021년 7월, 알데이라 테라퓨틱스는 원발성 유리체망막 림프종 치료를 위한 ADX-2191(안구 내 주사용 메토트렉세이트)에 대해 FDA 희귀의약품 지정을 받았습니다. 이는 안구 내 주사용으로 특별히 제형화된 최초의 메토트렉세이트 제제입니다. 따라서 이러한 요인들로 인해 해당 부문은 예측 기간 동안 시장을 주도할 것으로 전망됩니다.

지리적 시장 침투
북미는 2022년 시장 점유율의 약 37.4%를 차지했습니다.
특히 미국을 중심으로 한 북미 지역은 림프종 관련 안구암 발병률 증가, 제품 승인 증가, 임상 시험 건수 증가, 주요 시장 참여 기업의 존재 등의 요인으로 시장을 주도할 것으로 예상됩니다.
예를 들어, 2023년 4월, 폴리비(폴라투주맙 베도틴-피이크)는 리툭산(리툭시맙), 사이클로포스파미드, 독소루비신, 프레드니손(R-CHP)과 병용하여 이전에 치료받지 않은 미만성 거대 B세포 림프종(DLBCL) 성인 환자 치료제로 FDA 승인을 받았습니다.
또한, 안구암 발병률 증가는 이 지역 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 미국 암 협회의 2023년 보고서에 따르면 미국에서 약 3,490건의 새로운 안구 및 안와 악성 종양 사례가 발생할 것으로 예상되며, 그 대부분은 흑색종일 것입니다. 이러한 안구암 발병률 증가는 안구 내 림프종을 포함한 치료법 개선의 필요성을 강조합니다. 또한, 안구 및 안와 종양으로 인한 사망자 수가 약 430명에 달하는 것은 이 지역에서 의약품 개발의 중요성을 보여줍니다. 북미 지역에서 안구암, 특히 안구 내 림프종의 발병률이 증가함에 따라 안구 내 림프종 치료제에 대한 수요가 증가하고 향후 시장 성장을 견인할 것으로 예상됩니다. 따라서 이러한 요인들로 인해 북미 지역은 예측 기간 동안 시장을 주도할 것으로 전망됩니다.

COVID-19 영향 분석
COVID-19가 안구 내 림프종 시장에 미치는 영향은 현재 연구 중이며, 특히 이 희귀 질환에 대한 정보는 아직 부족합니다. 그러나 다른 연구 결과에 따르면 COVID-19는 일반적으로 안구 조직에 직접적인 손상을 주지 않는 것으로 나타났습니다.

더욱이, 주목할 만한 사례 보고에서는 티라브루티닙 치료를 받는 동안 코로나19에 감염된 안구 악성 림프종 환자에 대해 기술하고 있는데, 이는 두 질병을 동시에 앓는 사람들이 겪는 심각한 문제들을 보여줍니다. 또한, 환자의 인구 통계학적 특성을 살펴보는 것도 중요한데, 안구 림프종, 특히 안구 내 림프종 진단을 받은 대부분의 환자는 고령이거나 면역 체계를 약화시키는 기저 질환을 가지고 있기 때문입니다.
시장 세분화
유형별
• 유리체망막
• 포도막
약물 계열별
• 메토트렉세이트
• 시스플라틴
• 리툭시맙
• 기타
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
안구 림프종 치료 시장의 주요 글로벌 업체로는 Pfizer Inc., Fresenius Kabi, Teva Pharmaceuticals Inc., Genentech, Inc., Celltrion Healthcare Co.,Ltd., Viatris Inc., Sandoz International GmbH, F. Hoffmann-La Roche 등이 있습니다. 주요 기업으로는 AryoGen Pharmed, Hikma Pharmaceuticals PLC 등이 있습니다.

주요 개발 사항
• 2021년 7월 20일, Aldeyra Therapeutics는 원발성 유리체망막 림프종 치료를 위한 ADX-2191(안구 내 주사용 메토트렉세이트)에 대해 FDA 희귀의약품 지정을 받았습니다. 이는 안구 내 주사용으로 특별히 제형화된 최초의 메토트렉세이트 제제입니다.
보고서 구매 이유

• 유형, 약물 종류, 투여 경로, 유통 채널 및 지역별 글로벌 안구 내 림프종 치료 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위해

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별하기 위해

• 모든 세그먼트를 포함한 안구 내 림프종 치료 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 포함된 PDF 보고서

• 주요 기업의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일 제공 글로벌 안구 림프종 치료 시장 보고서는 약 61개의 표, 54개의 그림, 그리고 195페이지 분량으로 구성될 예정입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Intraocular lymphoma treatment Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.
Intraocular lymphoma is a rare type of B-cell lymphoma. It is formed in white blood cells known as lymphocytes. It is especially common in those over the age of 50 or those with compromised immune systems. Many persons who have this type of eye cancer also have primary central nervous system lymphoma (PCNSL).
The global intraocular lymphoma treatment market encompasses of various drugs such as methotrexate, rituximab, and cisplatin. The market is driven by the factors such as increasing number of people with compromised immune system, growing geriatric population, advancements in research.
Market Dynamics: Drivers and Restraints
The individual with weaker immune system are more susceptible to this disorder
Individuals with weaker immune systems, such as those with HIV/AIDS, organ transplant recipients on immunosuppressive therapy, and those with autoimmune illnesses receiving immunosuppressive pharmaceuticals, are significantly more susceptible to intraocular lymphoma.
For instance, according to the American Academy of Ophthalmology 2022 article, people whose immune systems do not work properly are at risk for getting primary intraocular lymphoma (PIOL). This type of lymphoma is almost always a type of lymphoma called non-Hodgkin’s B cell lymphoma, and it can develop in the retina and in the vitreous inside the eye.
Furthermore, according to the American Cancer Society 2022 article, also notes that people with weakened immune systems have an increased risk for non-Hodgkin lymphoma (NHL). Some long-term infections may increase a person’s risk of lymphoma by forcing their immune system to work harder than usual.
Thus, this increased susceptibility results in a larger patient pool, which drives the demand for intraocular lymphoma drugs. Pharmaceutical companies are increasingly focusing on creating specialized medicines for immunocompromised patients, while clinical trials and research activities are being encouraged to address the specific needs of this vulnerable population.
Market Dynamics: Restraint
The high cost of cancer treatments is a serious global burden, particularly in emerging and underdeveloped nations where government support for healthcare is restricted. This issue derives from the high costs of research and development, severe regulatory requirements, patent protection, and limited access to healthcare. Strategies such as promoting generic pharmaceuticals, negotiating drug pricing, expanding health insurance coverage, investing in research, creating international cooperation, and stressing cancer prevention and early diagnosis can be pursued to help ease this burden.
Segment Analysis
The global intraocular lymphoma treatment market is segmented based on type, drug class, route of administration, distribution channel and region.
The methotrexate segment accounted for approximately 41.2% of the intraocular lymphoma treatment market share
The methotrexate segment is expected to dominate the market with market share of 41.2%. Methotrexate, a chemotherapeutic medication, is commonly used to treat intraocular lymphoma because of its effectiveness in reducing cancer proliferation within the eyes. Methotrexate is a market leader due to its proven track record, relative price compared to newer medicines, and recognized therapeutic utility.
Furthermore, the increasing drug approval is expected drive the segment growth, for instance, in July 2021, Aldeyra Therapeutics has been granted FDA orphan drug designation to ADX-2191 (methotrexate for intravitreal injection) for treatment of primary vitreoretinal lymphoma. It is the first methotrexate preparation specifically formulated for intraocular injection. Thus, owing to the above factors the segment is expected to dominate over the forecast period.
Geographical Penetration
North America accounted for approximately 37.4% of the market share in 2022
The North America region particulary the U.S. is expected to dominate the market owing to the factors such as rising incidence of eye cancer cases with lymphoma, rise in product approvals, increasing number of clinical trial, and presence of key market players in this region
For instance, in April 2023, Polivy (polatuzumab vedotin-piiq) has been approved by the FDA for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Furthermore, the rising prevalence of eye cancer is likely to drive the market in this region. For instance, according to the American Cancer Society's report for 2023, there will be around 3,490 new instances of eye and orbit malignancies in the U.S., the majority of which will be melanomas. This increased prevalence of eye cancer highlights the critical need for improved treatments, including those for intraocular lymphoma. Furthermore, the estimated 430 deaths from eye and orbit tumors demonstrate the significance of developing medicines in the region. As the prevalence of eye cancer, especially intraocular lymphoma, rises in North America, demand for intraocular lymphoma medications is expected to rise and drive market growth in the future years. Thus, owing to the above factors the region is expected to dominate over the forecast period.
COVID-19 Impact Analysis
COVID-19's impact on the intraocular lymphoma market is currently being studied, with little information known especially on this rare kind of disease. However, results from other studies indicate that COVID-19 does not usually directly damage ophthalmic tissues.
Moreover, one notable case report described a patient with intraocular malignant lymphoma who contracted COVID-19 while receiving tirabrutinib treatment, demonstrating the significant issues experienced by people coping with both illnesses at the same time. Furthermore, patient demographics are critical to examine because most people diagnosed with lymphoma of the eye, particularly intraocular lymphoma, are old or have underlying health issues that weaken their immune systems.
Market Segmentation
By Type
• Vitreoretinal
• Uveal
By Drug Class
• Methotrexate
• Cisplatin
• Rituximab
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the intraocular lymphoma treatment market include Pfizer Inc., Fresenius Kabi, Teva Pharmaceuticals Inc., Genentech, Inc., Celltrion Healthcare Co.,Ltd., Viatris Inc., Sandoz International GmbH, F. Hoffmann-La Roche Ltd, AryoGen Pharmed, Hikma Pharmaceuticals PLC among others.
Key Developments
• On July 20, 2021, Aldeyra Therapeutics has been granted FDA orphan drug designation to ADX-2191 (methotrexate for intravitreal injection) for treatment of primary vitreoretinal lymphoma. It is the first methotrexate preparation specifically formulated for intraocular injection.
Why Purchase the Report?
• To visualize the global intraocular lymphoma treatment market segmentation based on type, drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of intraocular lymphoma treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.
The global intraocular lymphoma treatment market report would provide approximately 61 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Drug Class
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The individual with weaker immune system are more susceptible to this disorder
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. The high cost associated with the treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Epidemiology Analysis
5.2. Porter's Five Force Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Regulatory Analysis
5.6. Pipeline Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Vitreoretinal*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Uveal
8. By Drug Class
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.1.2. Market Attractiveness Index, By Drug Class
8.2. Methotrexate*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Rituximab
8.4. Cisplatin
8.5. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. U.K.
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. Australia
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Pfizer Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Fresenius Kabi
12.3. Teva Pharmaceuticals Inc.
12.4. Genentech, Inc.
12.5. Celltrion Healthcare Co.,Ltd.
12.6. Viatris Inc.
12.7. Sandoz International GmbH
12.8. F. Hoffmann-La Roche Ltd
12.9. AryoGen Pharmed
12.10. Hikma Pharmaceuticals PLC
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Pfizer Inc., 4.	Key Developments, Fresenius Kabi, Teva Pharmaceuticals Inc., Genentech, Inc., Celltrion Healthcare Co.,Ltd., Viatris Inc., Sandoz International GmbH, F. Hoffmann-La Roche Ltd, AryoGen Pharmed, Hikma Pharmaceuticals PLC

표 목록 (Tables)

List of Tables

Table 1 Global Intraocular Lymphoma Treatment Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Intraocular Lymphoma Treatment Market Value, By Drug Class, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Intraocular Lymphoma Treatment Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Intraocular Lymphoma Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Intraocular Lymphoma Treatment Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Intraocular Lymphoma Treatment Market Value, By Type,2022-2031 (US$ Million)

Table 7 Global Intraocular Lymphoma Treatment Market Value, By Drug Class, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Intraocular Lymphoma Treatment Market Value, By Drug Class,2022-2031 (US$ Million)

Table 9 Global Intraocular Lymphoma Treatment Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Intraocular Lymphoma Treatment Market Value, By Distribution Channel,2022-2031 (US$ Million)

Table 11 Global Intraocular Lymphoma Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Intraocular Lymphoma Treatment Market Value, By Region,2022-2031 (US$ Million)

Table 13 North America Intraocular Lymphoma Treatment Market Value, By Type,2022-2031 (US$ Million)

Table 14 North America Intraocular Lymphoma Treatment Market Value, By Drug Class,2022-2031 (US$ Million)

Table 15 North America Intraocular Lymphoma Treatment Market Value, By Distribution Channel,2022-2031 (US$ Million)

Table 16 North America Intraocular Lymphoma Treatment Market Value, By Country,2022-2031 (US$ Million)

Table 17 South America Intraocular Lymphoma Treatment Market Value, By Type,2022-2031 (US$ Million)

Table 18 South America Intraocular Lymphoma Treatment Market Value, By Drug Class,2022-2031 (US$ Million)

Table 19 South America Intraocular Lymphoma Treatment Market Value, By Distribution Channel,2022-2031 (US$ Million)

Table 20 South America Intraocular Lymphoma Treatment Market Value, By Country,2022-2031 (US$ Million)

Table 21 Europe Intraocular Lymphoma Treatment Market Value, By Type,2022-2031 (US$ Million)

Table 22 Europe Intraocular Lymphoma Treatment Market Value, By Drug Class,2022-2031 (US$ Million)

Table 23 Europe Intraocular Lymphoma Treatment Market Value, By Distribution Channel,2022-2031 (US$ Million)

Table 24 Europe Intraocular Lymphoma Treatment Market Value, By Country,2022-2031 (US$ Million)

Table 25 Asia-Pacific Intraocular Lymphoma Treatment Market Value, By Type,2022-2031 (US$ Million)

Table 26 Asia-Pacific Intraocular Lymphoma Treatment Market Value, By Drug Class,2022-2031 (US$ Million)

Table 27 Asia-Pacific Intraocular Lymphoma Treatment Market Value, By Distribution Channel,2022-2031 (US$ Million)

Table 28 Asia-Pacific Intraocular Lymphoma Treatment Market Value, By Country,2022-2031 (US$ Million)

Table 29 Middle East & Africa Intraocular Lymphoma Treatment Market Value, By Type,2022-2031 (US$ Million)

Table 30 Middle East & Africa Intraocular Lymphoma Treatment Market Value, By Drug Class,2022-2031 (US$ Million)

Table 31 Middle East & Africa Intraocular Lymphoma Treatment Market Value, By Distribution Channel,2022-2031 (US$ Million)

Table 32 Pfizer Inc.: Overview

Table 33 Pfizer Inc.: Product Portfolio

Table 34 Pfizer Inc.: Key Developments

Table 35 Fresenius Kabi: Overview

Table 36 Fresenius Kabi: Product Portfolio

Table 37 Fresenius Kabi: Key Developments

Table 38 Teva Pharmaceuticals Inc.: Overview

Table 39 Teva Pharmaceuticals Inc.: Product Portfolio

Table 40 Teva Pharmaceuticals Inc.: Key Developments

Table 41 Genentech, Inc.: Overview

Table 42 Genentech, Inc.: Product Portfolio

Table 43 Genentech, Inc.: Key Developments

Table 44 Celltrion Healthcare Co., Ltd.: Overview

Table 45 Celltrion Healthcare Co., Ltd.: Product Portfolio

Table 46 Celltrion Healthcare Co., Ltd.: Key Developments

Table 47 Viatris Inc.: Overview

Table 48 Viatris Inc.: Product Portfolio

Table 49 Viatris Inc.: Key Developments

Table 50 Sandoz International GmbH: Overview

Table 51 Sandoz International GmbH: Product Portfolio

Table 52 Sandoz International GmbH: Key Developments

Table 53 F. Hoffmann-La Roche Ltd: Overview

Table 54 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 55 F. Hoffmann-La Roche Ltd: Key Developments

Table 56 AryoGen Pharmed: Overview

Table 57 AryoGen Pharmed: Product Portfolio

Table 58 AryoGen Pharmed: Key Developments

Table 59 Hikma Pharmaceuticals PLC: Overview

Table 60 Hikma Pharmaceuticals PLC: Product Portfolio

Table 61 Hikma Pharmaceuticals PLC: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Intraocular Lymphoma Treatment Market Value,2022-2031 (US$ Million)

Figure 2 Global Intraocular Lymphoma Treatment Market Share, By Type, 2022 &2031 (%)

Figure 3 Global Intraocular Lymphoma Treatment Market Share, By Drug Class, 2022 &2031 (%)

Figure 5 Global Intraocular Lymphoma Treatment Market Share, By Distribution Channel, 2022 &2031 (%)

Figure 6 Global Intraocular Lymphoma Treatment Market Share, By Region, 2022 &2031 (%)

Figure 7 Global Intraocular Lymphoma Treatment Market Y-o-Y Growth, By Type, 2022-2031 (%)

Figure 8 Global Intraocular Lymphoma Treatment Market Y-o-Y Growth, By Drug Class, 2022-2031 (%)

Figure 9 Global Intraocular Lymphoma Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2031 (%)

Figure 10 Global Intraocular Lymphoma Treatment Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 11 North America Intraocular Lymphoma Treatment Market Value,2022-2031 (US$ Million)

Figure 12 Asia-Pacific Intraocular Lymphoma Treatment Market Value,2022-2031 (US$ Million)

Figure 13 Europe Intraocular Lymphoma Treatment Market Value,2022-2031 (US$ Million)

Figure 14 South America Intraocular Lymphoma Treatment Market Value,2022-2031 (US$ Million)

Figure 15 Middle East and Africa Intraocular Lymphoma Treatment Market Value,2022-2031 (US$ Million)

Figure 16 North America Intraocular Lymphoma Treatment Market Value,2022-2031 (US$ Million)

Figure 17 North America Intraocular Lymphoma Treatment Market Share, By Type, 2022 &2031 (%)

Figure 18 North America Intraocular Lymphoma Treatment Market Share, By Drug Class, 2022 &2031 (%)

Figure 19 North America Intraocular Lymphoma Treatment Market Share, By Distribution Channel, 2022 &2031 (%)

Figure 20 North America Intraocular Lymphoma Treatment Market Share, By Country, 2022 &2031 (%)

Figure 21 South America Intraocular Lymphoma Treatment Market Value,2022-2031 (US$ Million)

Figure 22 South America Intraocular Lymphoma Treatment Market Share, By Type, 2022 &2031 (%)

Figure 23 South America Intraocular Lymphoma Treatment Market Share, By Drug Class, 2022 &2031 (%)

Figure 24 South America Intraocular Lymphoma Treatment Market Share, By Distribution Channel, 2022 &2031 (%)

Figure 25 South America Intraocular Lymphoma Treatment Market Share, By Country, 2022 &2031 (%)

Figure 26 Europe Intraocular Lymphoma Treatment Market Value,2022-2031 (US$ Million)

Figure 27 Europe Intraocular Lymphoma Treatment Market Share, By Type, 2022 &2031 (%)

Figure 28 Europe Intraocular Lymphoma Treatment Market Share, By Drug Class, 2022 &2031 (%)

Figure 29 Europe Intraocular Lymphoma Treatment Market Share, By Distribution Channel, 2022 &2031 (%)

Figure 30 Europe Intraocular Lymphoma Treatment Market Share, By Country, 2022 &2031 (%)

Figure 31 Asia-Pacific Intraocular Lymphoma Treatment Market Value,2022-2031 (US$ Million)

Figure 32 Asia-Pacific Intraocular Lymphoma Treatment Market Share, By Type, 2022 &2031 (%)

Figure 33 Asia-Pacific Intraocular Lymphoma Treatment Market Share, By Drug Class, 2022 &2031 (%)

Figure 34 Asia-Pacific Intraocular Lymphoma Treatment Market Share, By Distribution Channel, 2022 &2031 (%)

Figure 35 Asia-Pacific Intraocular Lymphoma Treatment Market Share, By Country, 2022 &2031 (%)

Figure 36 Middle East & Africa Intraocular Lymphoma Treatment Market Value,2022-2031 (US$ Million)

Figure 37 Middle East & Africa Intraocular Lymphoma Treatment Market Share, By Type, 2022 &2031 (%)

Figure 38 Middle East & Africa Intraocular Lymphoma Treatment Market Share, By Drug Class, 2022 &2031 (%)

Figure 39 Middle East & Africa Intraocular Lymphoma Treatment Market Share, By Distribution Channel, 2022 &2031 (%)

Figure 40 Pfizer Inc.: Financials

Figure 41 Fresenius Kabi: Financials

Figure 42 Teva Pharmaceuticals Inc.: Financials

Figure 43 Genentech, Inc.: Financials

Figure 44 Celltrion Healthcare Co., Ltd.: Financials

Figure 45 Viatris Inc.: Financials

Figure 46 Sandoz International GmbH: Financials

Figure 47 F. Hoffmann-La Roche Ltd: Financials

Figure 48 AryoGen Pharmed: Financials

Figure 49 Hikma Pharmaceuticals PLC: Financials

세계 안구 림프종 치료 시장 – 2023-2030

Global Intraocular Lymphoma Treatment Market - 2023-2030